Willis Daniel, Kamat Ashish M
The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373 Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373 Houston, TX 77030, USA.
Hematol Oncol Clin North Am. 2015 Apr;29(2):237-52, viii. doi: 10.1016/j.hoc.2014.10.011. Epub 2015 Jan 9.
At present, radical cystectomy is a mainstay in the management of all bladder cancers, whether of conventional urothelial histology or variant. However, in the case of some variants, it is clearly not enough and multimodal therapy is an imperative. In other cases, systemic therapy might be ineffective or even detrimental if it leads to delay in surgery (ie, squamous cell carcinoma). Thus, identification of variant histology is a critical part of bladder cancer staging because such histology may require appropriately tailored therapy.
目前，根治性膀胱切除术是所有膀胱癌（无论是传统尿路上皮组织学类型还是变异型）治疗的主要手段。然而，对于某些变异型膀胱癌，根治性膀胱切除术显然是不够的，多模式治疗势在必行。在其他情况下，如果全身治疗导致手术延迟（如鳞状细胞癌），可能无效甚至有害。因此，识别组织学变异型是膀胱癌分期的关键部分，因为这种组织学类型可能需要适当的个体化治疗。
